Chemokines are a family of small cytokines, or proteins secreted by cells. Proteins are classified as chemokines according to shared structural characteristics such as small size (they are all approximately 8-10 kilodaltons in size), and the presence of four cysteine residues in conserved locations that are key to forming their 3-dimensional shape.
According to a recent study conducted by scientists at Emory University in Atlanta, the administration of broad-spectrum antibiotics in mice with malignant melanoma, an aggressive type of skin cancer, expedited their metastatic bone growth.
There is a lack of understanding as to why some people suffer from long-lasting symptoms after COVID-19 infection.
Our immune systems have the potential to find and destroy cancer cells. But cancer cells can be clever and develop tricks to evade the immune system.
Cells push and pull on surrounding tissue to move in groups as they form organs in an embryo, track down invading bacteria, and become cancerous and spread.
When the pro-inflammatory pair, a receptor called CCR2 and its ligand CCL-2, get together, it increases the risk of developing type 1 diabetes, scientists report.
A study headed by scientists at Massachusetts General Hospital unravels certain crucial factors required for the survival of immune cells in the fight against cancer.
Chemokines are small proteins that adhere to these chemokine receptors and regulate the behavior and movement of white blood cells.
Oncotarget published "Urine protein biomarkers of bladder cancer arising from 16-plex antibody-based screens" which reported that the current study examines urine samples from 66 subjects, comprising of 31 Urology clinic controls and 35 bladder cancer patients, using a Luminex based screening platform.
Researchers from the Garvan Institute of Medical Research have uncovered four new subtypes of cells within triple-negative breast cancer, which contain promising new therapeutic targets for the aggressive disease.
Volume 11, Issue 28 of Oncotarget features "Lipid and protein tumor markers for head and neck squamous cell carcinoma identified by imaging mass spectrometry" by Schmidt et. al. which reported that the authors used MALDI imaging mass spectrometry and immunohistochemistry to seek tumor-specific expression of proteins and lipids in HNSCC samples.
A novel molecule LIH383 developed by scientists at the Luxembourg Institute of Health binds to and inhibits a formerly unknown opioid receptor in the brain.
A team has revealed the existence of viable biomarkers of ovarian cancer by investigating the profiles of circular RNA expression.